Cue Biopharma, Inc. (CUE) has announced a 1-for-30 reverse stock split, set to take effect on April 23, 2026. This decision, approved at the company’s recent Annual Meeting, aims to boost the per-share market price and ensure compliance with Nasdaq’s minimum bid requirements. Following the split, the total number of shares will decrease from approximately 97.7 million to 3.3 million, although the number of authorized shares and par value will remain unchanged.
This move comes as CUE has struggled with its stock price, which has fluctuated between $0.16 and $1.03 in the past year, currently sitting at $0.53 after a 20% decline. The reverse split could attract institutional investors and improve market perception, potentially stabilizing the stock’s performance.
Market professionals should monitor CUE’s post-split trading dynamics, as the adjustment may influence liquidity and investor interest in the stock moving forward.
Source: nasdaq.com